Age: 58.0
Sex: F
Vaccine: COVID19
Symptoms: Vision blurred
Clinical narrative: 1st and 2nd dose, 10-15 days after blurred vision went awa/Within 48 hours, she started with blurred vision/it lasts for a while/This is the 3rd time she had blurred vision/Especially when she reads, it is blurry./She stopped driving because of that.; This spontaneous case was reported by a consumer and describes the occurrence of VISION BLURRED (1st and 2nd dose, 10-15 days after blurred vision went awa/Within 48 hours, she started with blurred vision/it lasts for a while/This is the 3rd time she had blurred vision/Especially when she reads, it is blurry./She stopped driving because of that.) in a 58-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 048A21A and 013626A) for COVID-19 vaccination.     No medical history was provided by the reporter.  Concomitant products included METFORMIN, LEVOTHYROXINE, LOSARTAN and HYDROCHLOROTHIAZIDE for an unknown indication.   On 07-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 08-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced VISION BLURRED (1st and 2nd dose, 10-15 days after blurred vision went awa/Within 48 hours, she started with blurred vision/it lasts for a while/This is the 3rd time she had blurred vision/Especially when she reads, it is blurry./She stopped driving because of that). At the time of the report, VISION BLURRED (1st and 2nd dose, 10-15 days after blurred vision went awa/Within 48 hours, she started with blurred vision/it lasts for a while/This is the 3rd time she had blurred vision/Especially when she reads, it is blurry./She stopped driving because of that.) outcome was unknown.            No treatment medications were reported by the reporter.  This case concerns a  58-year-old, female patient with no relevant medical history and with concomitant medications of Meformin, Levothyroxine, Losartan, and Hydrochlorothiazide, who experienced the unexpected event of Vision blurred. The events occurred approximately xx day after the second dose of mRNA-1273 Vaccine. The rechallenge was unknown since no information about the events of the first dose was disclosed. The patient's medical history of concomitant intake of Meformin, Levothyroxine, Losartan, and Hydrochlorothiazide  remain as confounders for the occurrence of the events. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report.   This case was linked to MOD-2021-379644, MOD-2021-379516 (Patient Link).; Sender's Comments: This case concerns a  58-year-old, female patient with no relevant medical history and with concomitant medications of Meformin, Levothyroxine, Losartan, and Hydrochlorothiazide, who experienced the unexpected event of Vision blurred. The events occurred approximately xx day after the second dose of mRNA-1273 Vaccine. The rechallenge was unknown since no information about the events of the first dose was disclosed. The patient's medical history of concomitant intake of Meformin, Levothyroxine, Losartan, and Hydrochlorothiazide  remain as confounders for the occurrence of the events. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report.